Our Pipeline

The flexibility of our innovative SANGs platform enables a broad developmental pipeline with multiple oncological indications and different therapeutic agents, maximizes the potential for translational success. We are actively completing our remaining IND-enabling studies with our sights set on first-in-human trials and advancing preclinical studies across a variety of additional solid tumor indications and are credentialing additional therapeutic targets.